Results
- Sixty-four per cent (n=118) of patients newly initiated on a DOAC were followed-up within 4 weeks.
- Ninety-two per cent (n=166) of patients were initiated on an appropriate dose of DOAC in accordance with product licence.
- Fifteen per cent (n=27) of patients had either a dose or DOAC changed, or DOAC stopped at the follow-up appointment by a pharmacist.
- The majority of alterations were due to incorrect documentation of weight, use of old blood test results and use of eGFR instead of calculated creatinine clearance (CrCl) using Cockroft and Gault.
- The majority of patients were followed up within a 4 week period. A significant proportion, 8% (n=17), required dose amendments, as initial dosing was incorrectly based on CrCl estimated by the hospital system which is based on e-GFR and not Cockroft and Gault in line with the product licences and clinical trials.

Conclusion Pharmacists have a clear role in ensuring appropriate dosing of DOACs and a reminder (and education) for non-specialist pharmacists on the importance of dosing based on CrCl with Cockroft and Gault, as opposed to the default on hospitals with e-GFR.

REFERENCE AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

4CPS-018 EVALUATION OF ANTIPLATELET AGENT PRESCRIBING IN PATIENTS ON DIRECT ORAL ANTICOAGULANT
10.1136/ejhpharm-2019-eahpconf.167

Background Among patients requiring an oral anticoagulant (OAC), a large proportion also take an antiplatelet agent (AP). Several studies have highlighted the significantly increased bleeding risk associated with a combined OAC (VKA mainly) and AP (aspirin mainly) therapy, without a reduction in risk of recurrence of coronary artery events or thromboembolism. The continuation of an AP in patients on OAC therapy for venous thromboembolism or atrial fibrillation remains a recurrent matter of debate and is still little studied in patients on direct OAC (DOAC).

Purpose Our main objective was to evaluate to what extent combined DOAC-AP therapy met recommendations of current guidelines. A secondary objective was to describe antithrombotic prescription schemes in patients on DOAC with a recent history of recurrence of coronary artery events or thromboembolism. Non-specialist pharmacists on the importance of dosing based on CrCl and not Cockroft and Gault in line with the product licences and clinical trials.

Material and methods We performed an observational retrospective cohort study in a 450-bed teaching hospital. Among DOAC patients prospectively reviewed by a clinical pharmacist dedicated to anticoagulation between January and December 2018 to July 2018 for patients attending anticoagulant clinics.

10.1136/ejhpharm-2019-eahpconf.166
2016, we selected patients with a concomitant DOAC and AP prescription during their hospitalisation. Medical history, clinical and medication data were retrieved from the electronic medical record. Based on current guidelines, a decision tool was developed to evaluate the appropriateness of combined DOAC-AP therapy according to three classifications: ‘likely appropriate’ (i.e. in line with current guidelines); ‘out of guidelines’; and ‘debatable’. Evaluations were performed first by the clinical pharmacist. Complex cases were then discussed with specialist physicians.

**Results** Among 336 patients screened, 106 (31%) received combined DOAC-AP therapy during their hospitalisation. Fifty-two prescriptions (49%) were considered as ‘likely appropriate’, 51 (48%) were rated as ‘out of guidelines’ (including 27 patients with stable coronary artery disease) and no consensus was achieved for three (3%; judged as ‘debatable’). Eighteen patients had undergone a PCI in the past 6 months. The antiplatelet scheme was a combination of aspirin and clopidogrel in 14 (82%) patients and DOAC prescription during their hospitalisation. Medical history, clinical and medication data were retrieved from the electronic medical record. Based on current guidelines, a decision tool was developed to evaluate the appropriateness of combined DOAC-AP therapy according to three classifications: ‘likely appropriate’ (i.e. in line with current guidelines); ‘out of guidelines’; and ‘debatable’. Evaluations were performed first by the clinical pharmacist. Complex cases were then discussed with specialist physicians.

**References and/or acknowledgements**

No conflict of interest.

---

**4CPS-019 MEDICATION USE EVALUATION OF EDOXABAN IN A TERTIARY HOSPITAL**

J Park*, JH You, SM Lee, YS Lee, HK Lee, JM Kim. Samsung Medical Centre, Department of Pharmacy, Seoul, South Korea

10.1136/ejhpharm-2019-eahpconf.168

**Background** A new oral anticoagulant (NOAC) edoxaban, which causes less drug-drug or drug-food interactions than warfarin and does not require routine international normalised ratio (INR) monitoring, is associated with a better safety profile in those with renal impairment or low bodyweight, and the elderly.

**Purpose** To analyse the trend and the appropriateness of edoxaban prescriptions in a tertiary hospital.

**Material and methods** A retrospective study was conducted using the electronic medical records between April 2016 and August 2017. Patients who initiated treatment with edoxaban between April 2016 and August 2016 were included. We analysed the data to assess if the indications and dosage were appropriate based on the labelling recommendations. We also followed patients’ treatment outcomes and adverse events.

**Results** In total, 142 patients were treated with edoxaban during the observation period. In 94.4% of these patients, edoxaban was prescribed for proper indications, except for eight patients who lacked approved indication for edoxaban use: six were being treated for valvular atrial fibrillation and two for suspected arterial embolism. Among 134 patients with appropriate indications, the percentages of patients whose renal function and bodyweight were measured before initial dosing were 85.8% and 94.0%, respectively. Of the 30 patients who switched from warfarin to edoxaban, 21 patients (70.0%) started edoxaban when the INR £2.5. Ninety-three of 134 patients (69.4%) received appropriate an initial dose based on renal function, bodyweight and drug interactions. Thirty patients needed dose modification during administration, but dose adjustments were performed only in eight patients. Twenty patients (14.9%) had adverse drug events, with a total of 30 events, 22 of which were related to bleeding. During the study period, stroke occurred in two patients and no evidence of stroke or pulmonary embolism was observed in 123 patients. Nine patients were lost to follow-up.

**Conclusion** The majority (>90%) of patients in our study had indications adequate for edoxaban use, but only 70% of patients received appropriate interventions in terms of dose adjustment and transitioning between anticoagulants. Of the 30 cases of adverse events, 73.3% were bleeding-related events. Therefore, pharmacists need to make more efforts to improve the safe and effective use of edoxaban.

---

**4CPS-020 ANTICOAGULATION THERAPY IN HAEMODIALYSIS – A CLINICAL PHARMACIST EXPERIENCE IN A PRIMARY CARE TEAM**

1 A Szabó*, 2 Á Harts, 3 S Dolgos, 1 Cseh. 1Szent Margit Hospital, Central Pharmacy Department, Budapest, Hungary; 2 Szent Margit Hospital, Nephrology Department, Budapest, Hungary

10.1136/ejhpharm-2019-eahpconf.169

**Background** Anticoagulation (AC) is essential to haemodialysis (HD), however the uremic state itself can cause bleeding complications.

**Purpose** The aims of this retrospective cohort study were:

- To evaluate our current anticoagulation practice focusing on bleeding risk in contrast to thromboembolic events.
- To analyse potentially severe drug–drug interactions (DIs) to determine drug combinations that should be avoided.

**Material and methods** We reviewed the medical records of 101 chronic HD patients (55 men, age 69±12 years, HD vintage 31 months (IQR:43)) in our hospital. Each patient’s current medical treatment was evaluated by in-person interview and drug interactions were checked with Medscape. Statistical analysis was performed with the SPSS v18.0 software package. Data were expressed as mean ±SD, comparisons between groups were analysed by non-parametric tests, p<0.05 was considered statistically significant.

**Results** A total of 69 patients received UFH and 31 got LMWH during HD as per dialysis protocol. For other indications 20 patients received LMWH and 11 patients received oral anticoagulation therapy (OAC) off-dialysis days. The majority of patients spent a longer time outside of target international normalisation ratio. Additionally, 41 patients took antithrombotic agents and 29 took NSAIDs. Overall, 34% of the total patients had experienced bleeding, while 30% had suffered thromboembolic complications.

Fifty-four (45%) patients had 83 severe/contraindicated DIs. The main severe potential drug-drug interactions were caused by combinations of NSAID/ASA (35%), dalteparin/UFH (29%) and dalteparin/clopidogrel (10%). Sixty-eight per cent of these patients (31 out of 45) had manifest bleedings, whereas among those without drug interactions bleeding was observed in 18% (p<0.001). More blood transfusions (64%)